Company: SXTPW
Filing Date: 2025-01-30
Form Type: 424B5
Source: 0001213900-25-008098
Chunk: 57

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-01-30
Form: 424B5
Chunk 57
---
 www.arakoda.com. |

| 26 | See                                         
 prescribing information at www.arakoda.com. |

| 27 | Dow                                                     
 and Smith, New Microbe and New Infect 2022; 45: 100964. |

| 28 | Queener                                                                                                                            
 et al Journal of Infectious Diseases 1992;165:764-8).                                                                              |
| 29 | Liu                                                                                                                                
 et al. Antimicrobial Agents Chemo 2021;65:e00204-21, Marcos et al. IDCases 2022;27:e01460; Rogers et al. Clin Infect Dis. 2022 Jun 
 10:ciac473, Prasad and Wormsner. Pathogens 2022;11:1015.                                                                           |

| 30 | Krause                                               
 et al Clin Infect Dis 2024; doi:10.1093/cid/ciae238. |

<div align='center'>5</div>

Celgosivir Celgosivir is a host targeted glucosidase inhibitor that was developed separately by other sponsors for HIV then for hepatitis C. 31The sponsors abandoned Celgosivir after completion of Phase II clinical trials involving 700+ patients, because other antivirals in development at the time had superior activity. The National University of Singapore initiated development of Celgosivir independently for Dengue fever. A clinical study, conducted in Singapore, the results of which were accepted for publication in the peer-reviewed journal Lancet Infectious Diseases, confirmed its safety but the observed reduction in viral load was lower than what the study was powered to detect. 32Celgosivir (as with other Dengue antivirals) exhibits greater capacity to cure Dengue infections in animal models when administered prior to symptom onset when compared to administration post-symptom onset. In animal models, this problem can be addressed by administering the same dose of drug split into four doses per day rather than two doses per day (as was the case in the Singaporean clinical trial). 33This observation led to the filing and approval of a patent related to Dengue, which we licensed from the National University of Singapore. Additional clinical studies would be required to prove that such a 4x daily dosing regimen would be safe and effective in Dengue patients to regulators’ satisfaction. To that end, earlier in our history, we, in partnership with the National University of Singapore, and Singapore General Hospital, successfully secured a grant from the government of